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DNA microarrayZinc ﬁnger, MYND-type containing 8 (ZMYND8) encodes a receptor for activated C-kinase protein.
Here, we report that ZMYND8 promotes angiogenesis in prostate cancer xenografts in zebraﬁsh,
as well as tube formation in human umbilical vascular endothelial cell (HUVEC) cultures. Using tran-
scriptome analyses, we found upregulation of ZMYND8 expression in both zebraﬁsh prostate cancer
xenografts and prostate cancer samples from patients. In vitro and in vivo ZMYND8 knockdown sup-
pressed angiogenesis, whereas ZMYND8 overexpression enhanced angiogenesis. Notably, ZMYND8
induced vegfa mRNA expression selectively in prostate cancer xenografts. Integrated analysis of
human and zebraﬁsh transcriptomes, which identiﬁed ZMYND8, might be a powerful strategy to
determine also other molecular targets for inhibiting prostate cancer progression.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Because tumour-associated angiogenesis is crucial for solid
malignancies including prostate cancer, inhibition of tumour neo-
vascularization and/or destruction of tumour vasculature might
maintain tumours in a dormant state or, in combination with cyto-
toxic therapies, may potentiate tumour shrinkage. Molecular tar-
geted agents (mainly antagonists of vascular endothelial growth
factor [VEGF] pathways) have been developed to block proangio-
genic signal transduction. For example, bevacizumab, a humanized
antibody against VEGF-A, was the ﬁrst antiangiogenic agent to be
approved for treatment of several advanced cancers [1]. Further-
more, sunitinib, a small molecule that blocks intracellular VEGF,
KIT, Flt3, and platelet-derived growth factor receptors, regulates
angiogenesis and cell growth, and has been approved for treatment
of advanced renal cell cancer and malignant gastrointestinal stro-mal tumours [2]. However, there are still a limited number of tar-
get molecules to inhibit cancer progression including tumour
angiogenesis and metastasis. To overcome this limitation, several
approaches based on screening and omics technologies together
with animal modelling have been developed for target discovery
and validation.
Various animal models have been established to investigate
angiogenic processes and identify proangiogenic and antiangio-
genic compounds. Over the last few decades, the zebraﬁsh as a dis-
ease model has emerged as a high throughput and cost effective
alternative to other animal models, which has been used to assess
the efﬁcacy and toxicity of several chemical compounds [3,4]. In
cancer research, xenografts of various cancer cell lines induce neo-
vascularization in zebraﬁsh [5–8]. Furthermore, a high degree of
conservation of the pathways involved in tumourigenesis, angio-
genesis, and metastasis has been proven in zebraﬁsh and mammals
[9,10]. Zebraﬁsh also present powerful imaging solutions through
in vivo ﬂuorescent labelling of desired organs such as the vascula-
ture system in combination with their body wall transparency [11].
Because the zebraﬁsh is exploitable for genome-wide, loss-of-func-
tion analyses, we used human cancer-xenografted zebraﬁsh in
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sense oligonucleotide (MO) knockdown, and found a new thera-
peutic target, zinc-ﬁnger MYND-type containing 8 (zmynd8), for
inhibition of tumour angiogenesis.
2. Materials and methods
An expanded Methods section is available in the online-only
Data Supplement.
2.1. Ethics approval
This study was approved by the Ethics Committee of Mie Uni-
versity. The procedures were performed according to the Japanese
animal welfare regulation ‘Act on Welfare and Management of Ani-
mals’ (Ministry of Environment, Japan) and complied with interna-
tional guidelines.
2.2. Chemicals
LY317615 and Ly333531 were purchased from Selleck Chemi-
cals (Houston, TX, USA) and Tocris Bioscience (Bristol, UK), respec-
tively. Stock solutions (10 mM) were prepared by dissolving the
chemicals in dimethyl sulfoxide (Sigma–Aldrich, St. Louis, MO,
USA). For anaesthesia, 100 ppm 2-phenoxyethanol (2-PE; Tokyo
Kasei, Tokyo, Japan) was diluted in E3 medium (5 mM NaCl,
0.17 mM KCl, 0.4 mM CaCl2, and 0.16 mM MgSO4).
2.3. Zebraﬁsh
The care and breeding of zebraﬁsh followed previously
described protocols [12]. Because of the transparency of their
bodies, which facilitates in vivo monitoring of tumour angiogene-
sis, nacre/ﬂi1:egfp zebraﬁsh obtained by cross-breeding nacre
mutants [13] and ﬂi1:egfp transgenic zebraﬁsh [11] were used in
the experiments. At 3 days prior to xenotransplantation, individual
female zebraﬁsh were placed in mating tanks with males. The next
morning, mating was initiated by light stimuli, followed by
collection of the resulting fertilized eggs. The eggs were incubated
in E3 medium at 28 C. Preceding xenotransplantation, 48 h post-
fertilization (hpf) embryos were dechorionated using a 2 mg/ml
pronase solution (Roche Diagnostics, Mannheim, Germany) as
described previously [12]. After dechorionation, the embryos were
anaesthetized by immersion in 100 ppm 2-PE. Then, the embryos
were arrayed onto an embryo-holding sheet for xenotransplanta-
tion procedures.
2.4. DU145-Kusabira orange (KOr) cell xenotransplantation
DU145 human prostate cancer cells were obtained from the
RIKEN Cell Bank (Tokyo, Japan), and DU145 cells stably expressing
Kusabira orange (KOr) (DU145-KOr cells) were established as
described in Supplementary Methods. DU145-KOr xenotransplan-
tation was conducted according to a previous report [8] with some
modiﬁcation. DU145-KOr cells (1  106 cells) were suspended in
30 ll Matrigel (BD Biosciences, San Jose, CA, USA) at 4 C. The glass
needles used to inject the cells were prepared from GD-1 glass cap-
illaries (Narishige, Tokyo, Japan) using a PP-830 gravity puller
(Narishige) and ﬁnely polished with an EG-44 microforge (Narish-
ige). The avascular region of the yolk sac was then injected with
10 nl of the cell suspension containing 100–200 cells using a glass
needle and FemtoJet injection system (Eppendorf, Hamburg, Ger-
many). The xenografted zebraﬁsh were subsequently incubated
in E3 medium at 32 C. At 48 hpi, 80–90% of the injected zebraﬁsh
exhibited tumours in their yolk sac.2.5. Imaging of xenotransplants in zebraﬁsh
Zebraﬁsh were anesthetised with 100 ppm 2-PE. Images were
then captured under a MZ16F stereoscopic microscope (Leica
Microsystems, Wetzlar, Germany) equipped with a DP71 digital
camera (Olympus, Tokyo, Japan). For ﬂuorescence imaging, we
used GFP2 (for ﬂi1:egfp) and DsRed (for KOr) ﬁlters. Tumour cell
proliferation was calculated by the ratio of the KOr ﬂuorescence
intensity in the tumour area with ImageJ software (National
Institutes of Health, Bethesda, MD, USA) as described previously
[14].2.6. cDNA synthesis and quantitative RT-PCR (qRT-PCR)
Total RNA was extracted from DU145-xenografted zebraﬁsh at
48 h post-implantation (hpi) using Trizol reagent (Life Technolo-
gies, Carlsbad, CA, USA) in combination with a cleanup protocol
(RNeasy Mini Kit; Qiagen, Hilden, Germany). First-strand cDNA
was synthesized from 200 ng total RNA using a Super Script III
cDNA synthesis kit (Life Technologies) and random primers (Life
Technologies). qRT-PCR was performed using Power SYBR Green
Master Mix (Applied Biosystems, Foster City, CA, USA) and a
7300 real-time PCR system (Applied Biosystems) as recommended
by the manufacturer. The target gene was ampliﬁed using the
primers shown in Table S1. Data were normalized to the mRNA
level of beta-2-microglobulin (human B2M, NM_004048; zebraﬁsh
b2m, NM_001159768).
2.7. DNA microarrays
Total RNA was extracted from DU145-xenografted zebraﬁsh at
48 hpi with or without tumour angiogenesis as described above.
The samples for each condition were obtained from three indepen-
dent experiments. Each experimental group included 5–10 xeno-
grafts. Detailed methods for the DNA microarray analysis are
described in Supplementary Methods.
2.8. MOs
Based on the cDNA sequences in GenBank for zebraﬁsh zmynd8
(XM_687794) and vascular endothelial growth factor aa (vegfaa)
(NM_131498), MOs against zfZMYND8 (zfZMYND8 MO) and
zfVEGFAa (zfVEGFAa MO) were synthesized by Gene Tools (Philo-
math, OR, USA). For the negative control, we used a control MO
(human b-globin mutant sequence; GeneTools). The MO sequences
are shown in Table S1. Each MO was injected into the yolk sac
(48 hpf) with or without DU145-KOr cells using a ﬁne glass needle
connected to the FemtoJet automatic injector. To conﬁrm the MO
distribution, we injected lissamine-conjugated control MO (Gene-
Tools) into 48 hpf embryos (Fig. S1). One hundred picoliters of
100 lM MO in water was injected in accordance with a previous
report [15].
2.9. ZMYND8 mRNA synthesis and rescue
pCMV-SPORT6.1 carrying full-length human ZMYND8 cDNA
was obtained from Open Biosystems (Huntsville, AL, USA) and sub-
cloned into a pTnT vector (Promega, Madison, WI, USA). The full-
length human ZMYND8 cDNA was then ampliﬁed by PCR, and
the PCR products were used as templates for RNA synthesis.
ZMYND8 mRNA was synthesized using a mMessage mMachine
transcription kit for T7 RNA polymerase (Ambion, Austin, TX,
USA). For the rescue experiment, a solution containing 0.5 ng/nl
ZMYND8 mRNA and 8 ng zfZMYND8-MO was injected into 48
hpf embryos with xenotransplants.
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3.1. Transcriptome analyses reveal an increase in zmynd8 expression
during tumour angiogenesis
DU145-KOr cell implantation into the avascular region of the
yolk sac of 48 hpf zebraﬁsh induced tumour angiogenesis in 34%
of the xenografted animals at 48 hpi (of the 124 injected zebraﬁsh
eggs, 107 developed tumours [xenografted] and 36 of these xeno-
grafted zebraﬁsh underwent tumour angiogenesis). The tumour
vessels were elongated from common caudal veins and/or subin-
testinal veins surrounding the implanted cancer cells, which were
not observed in control zebraﬁsh (Fig. 1A). Tumour sizes were sig-
niﬁcantly increased in the angiogenesis (+) group (P < 0.05;
Fig. 1B), suggesting that the tumour vessels contributed to cancer
cell proliferation in DU145-KOr xenografts.
DNA microarray analyses were performed using total RNA from
DU145-xenografted zebraﬁsh. In the tumour angiogenesis (+)
group, 36 and 172 genes showed signiﬁcantly (false positive rate
[FDR]<0.1) decreased or increased expression, respectively, com-
pared with that in the angiogenesis () group (Table S2). Blast
analyses [16] revealed that the zebraﬁsh genes with decreased or
increased expression represented 17 and 96 human orthologs,
respectively. Analysis of these genes by Gene Ontology (GO) terms
using GOstat [17] revealed that 16.8% and 9.7% of their human
orthologs are involved in apoptosis and protein kinase activity,
respectively (Table S3). To determine the genes responsible for
tumour angiogenesis, we analysed the transcriptome data of
human clinical samples, [GSE3325 [18], GSE6605 [19], GSE6919
[20], and GSE27616 [21]], and our zebraﬁsh DNA microarray data.
Among these data, the expression of three genes was signiﬁcantly
(FDR < 0.1) increased or decreased during cancer progression com-
pared with that in normal tissues (Table 1). Of the three genes,
qRT-PCR analyses conﬁrmed the DNA microarray results indicating
that zmynd8 expression was increased by almost 4-fold duringFig. 1. ZMYND8 expression increases during cancer progression. (A) Typical images of DU
xenografted zebraﬁsh exhibited tumour angiogenesis. The lower images are enlarged vie
was increased in tumour angiogenesis (+) zebraﬁsh at 96 hpf. n = 12, ⁄P < 0.05. (C) Zebr
DU145 xenografts with tumour angiogenesis. n = 5, ⁄P < 0.01, P < 0.05 and P < 0.01 vs. co
clinical prostate cancer specimens (GSE3324 and GSE6909). n = 6–7, ⁄P < 0.05, ⁄⁄P < 0.01 v
at each stage, respectively. (E) Immunostaining of human ZMYND8 in clinical prostate ctumour angiogenesis compared with that in the non-xenografted
control and angiogenesis () group (P < 0.01; Fig. 1C). Zebraﬁsh
zmynd8 protein shows 67% similarity and 77% identity with
human ZMYND8 in BLAST analysis [22]. While the similarity of
the amino acid sequences is moderate in zebraﬁsh and human
ZMYND8 proteins, the similarity in each functional domain (zinc
ﬁnger domain at the N-terminus, bromodomain, PWWP domain,
and zinc ﬁnger MYND-type domain) is very high (88–100%;
Fig. S2). This ﬁnding indicates that the pathophysiological function
of ZMYND8 would be highly conserved in vertebrates. Notably,
human ZMYND8 mRNA was also increased during tumour angio-
genesis (P < 0.01; Fig. 1C). To determine whether the protein levels
of ZMYND8 were also altered in prostate cancers, we conducted
immunohistochemistry using human prostate cancer tissue micro-
arrays (Fig. 1D). In normal prostate, ZMYND8 was expressed in
glandular and vascular epithelia, but not in connective tissues. In
prostate cancer tissues, ZMYND8 was expressed in cancer cells,
but not in stromal cells. Human ZMYND8 expression was increased
at the neoplastic stage (P < 0.01 vs. normal prostate tissues), and
particularly at the metastatic stage IV (P < 0.05 vs. stage I; Fig. 1E).
3.2. ZMYND8 regulates tumour angiogenesis in DU145-xenografted
zebraﬁsh
To analyse the role of zebraﬁsh zmynd8 in tumour angiogene-
sis, we co-injected zfZMYND8MO and DU145-KOr cells into zebra-
ﬁsh at 48 hpf. As a result, zfZMYND8 MO decreased the expression
of zmynd8 protein (P < 0.05 vs. control MO; Fig. 2A and B). Similar
to co-injection of vegfab MO (zfVEGFAbMO) as the positive control
(Fig. S3), zfZMYND8 MO co-injection with DU145-KOr cells sup-
pressed tumour angiogenesis (Fig. 2C). Furthermore, the frequency
of tumour angiogenesis was suppressed signiﬁcantly (P < 0.05;
Fig. 2D), while the tumour size was not changed by zfZMYND8
MO (Fig. 2E). Yolk sac injection of these MOs at 48 hpf did not alter
physiological angiogenesis at 96 hpf (Fig. S4). Because the145-xenografted zebraﬁsh. Arrow indicates tumour vessels. Almost 34% of DU145-
ws of the outlined areas. White arrows indicate tumour vessels. (B) The tumour size
aﬁsh zmynd8 (left) and human ZMYND8 (right) mRNA expression was increased in
ntrol (no xenograft or cultured cells, respectively). (D) ZMYND8mRNA expression in
s. normal tissue. ⁄P < 0.05. GSE3324 and GSE6909 include 6–7 and 18–25 specimens
ancer specimens. n = 3–7, ⁄P < 0.05 vs. stage I, P < 0.01 vs. normal tissue.
Table 1
Genes with altered expression in zebraﬁsh and human prostate cancer progression.
Gene symbol Zebraﬁsh xenograft Human prostate cancer Human prostate cancer Human prostate cancer Human prostate cancer
(GSE3325) (GSE6605) (GSE6919) (GSE27616)
Log2 ratio FDR Log2 ratio FDR Log2 ratio FDR Log2 ratio FDR Log2 ratio FDR
TARS 2.47 0.01 1.18 0.01 0.54 0.02 1.84 0 0.03 0.78
ZMYND8 1.33 0.02 1.51 0.02 1.49 0 1.78 0 0.71 0.00
IRF7 1.21 0.02 1 0.04 1.73 0 0.81 0 0.00 0.97
Fig. 2. ZMYND8 is involved in tumour angiogenesis. (A) Western blot of control zebraﬁsh injected with zfZMYND8 MO or HuZMYND8 mRNA at 48 hpf. The lysate was
prepared at 96 hpf. (B) Densitometric analysis of (A). Compared with the control MO, zfZMYND8 MO decreased zmynd8 protein expression to 50%, whereas HuZMND8 mRNA
increased ZMYND8 protein expression by 2.5-fold compared with that in the control. n = 3–4, ⁄P < 0.05. (C) Typical images of zfZMYND8 MO and human ZMYND8 rescue in
DU145-xenografted zebraﬁsh at 96 hpf. zfZNYND8MO suppressed tumour angiogenesis and HuZMYND8mRNA rescued the effect of zfZNYND8MO. (D) Frequency analysis of
(C). Tumour angiogenesis was decreased and increased by zfZMYND8 MO and HuZMYND8 mRNA, respectively. n = 3, ⁄P < 0.05. Each experimental group included 27–49
zebraﬁsh. (E) Tumour proliferation of (C). n = 91–114, ⁄P < 0.05.
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ducted human ZMYND8 (HuZMYND8) mRNA rescue (Fig. 2A). As
shown in Fig. 2C and D, HuZMYND8 mRNA co-injection promoted
tumour angiogenesis with or without zebraﬁsh zmynd8 knock-
down. Because of the differences in the amino acid sequences of
zfZMYND8 and HuZMYND8, zfZMYND8 MO could not suppress
the translation of HuZMYND8 mRNA. Therefore, the zfZMYND8
MO-induced reduction of tumour angiogenesis was recovered by
introduction of HuZMYND8 mRNA. Consequently, the tumour size
of xenotransplanted cancer cells was increased signiﬁcantly
(P < 0.05; Fig. 2E).3.3. ZMYND8 knockdown suppresses tube formation of human
umbilical vein endothelial cells (HUVECs)
To evaluate the functional similarity between human and zeb-
raﬁsh ZMYND8, we conducted capillary tube formation experi-
ments using HUVECs with siRNA-mediated knockdown of Human
ZMYND8 (Fig. 3A). Human ZMYND8 knockdown did not affect
HUVEC proliferation (Fig. 3B), but their capacity for tube formationwas drastically suppressed by all ZMYND8 siRNAs (P < 0.01; Fig. 3C
and D). These results are consistent with those of zebraﬁsh xeno-
graft experiments (Fig. 2).3.4. Human ZMYND8 in DU145-KOr cells regulates tumour growth in
DU145-xenografted zebraﬁsh
The expression of human ZMYND8 was increased in tumour
xenografts (Fig. 1C) and human clinical samples (Fig. 1D,E and
Table 1). Therefore, we conducted xenotransplantation with
ZMYND8 knockdown or overexpression in DU145-KOr cells
(Figs. 4A and S5). Similar to the results obtained with HUVECs
(Fig. 3B), ZMYND8 knockdown or overexpression did not affect
DU145-KOr cell proliferation (Figs. 4B and S6). In contrast to zebra-
ﬁsh zmynd8 knockdown, DU145-KOr cells with ZMYND8 knock-
down had no effect on tumour angiogenesis in xenografted
zebraﬁsh, whereas ZMYND8 overexpression increased tumour
angiogenesis (Fig. 4C and D). The sizes of the tumour xenografts
were also increased by ZMYND8 overexpression, which corre-
sponded to tumour angiogenesis (Fig. 4E).
Fig. 3. Human ZMYND8 knockdown suppresses tube formation. (A) ZMYND8 siRNA transfection of HUVECs. ZMYND8 knockdown was conﬁrmed by qRT-PCR. n = 4, ⁄P < 0.01.
(B) ZMYND8 knockdown did not affect HUVEC proliferation. n = 8. (C) ZMYND8 knockdown suppressed tube formation of HUVECs. (D) Quantitative analysis of (C). A decrease
in the tube area was induced by each ZMYND8 siRNA. n = 8, ⁄P < 0.01 vs. NC siRNA.
Fig. 4. Human ZMYND8 modulation in DU145-KOr cells. (A) Human ZMYND8 knockdown (ZMYND8 siRNA) and overexpression (HuZMYND8-OE) in DU145-KOr cells were
conﬁrmed by qRT-PCR. n = 3–4, ⁄⁄P < 0.01. (B) ZMYND8 modulation did not affect DU145-KOr cell proliferation. n = 8. (C) Typical images of ZMYND8-modulated DU145-
xenografted zebraﬁsh. (D) Angiogenesis frequency analysis of ZMYND8-modulated DU145-KOr cell xenotransplantation. HuZMYND8-OE increased tumour angiogenesis in
DU145-xenografted zebraﬁsh at 48 hpi. n = 3, ⁄P < 0.05. Each experimental group included 17–25 zebraﬁsh. (E) Tumour cell proliferation of (D). n = 53–67, ⁄P < 0.05.
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Because hypoxia promotes pathophysiological angiogenesis in
several diseases including cancer, we conducted hypoxic treatment
of developing zebraﬁsh. As shown in Fig. S7, zmynd8 expression
was induced together with hypoxia-inducible factor 1 (hif1a), vegfaa,
vegfab, and vegfc under hypoxic conditions at 72 hpf. To investigate
the relationship between ZMYND8 and VEGF signalling, we con-
ducted qRT-PCR analysis of vegf isoforms and receptors in
DU145-xenografted zebraﬁsh treated with zfZMYND8 MO and
HuZNYND8 mRNA (Fig. 5). As a result, zmynd8 regulated the
expression of vegfaa and vegfab isoforms (P < 0.05 vs. DU145-xeno-
grafted zebraﬁsh; Fig. 5A and B), but not vegfc (Fig. 5C). In addition,
zfZMYND8 MO did not suppress the expression of vegf receptors,
whereas HuZMYND8 mRNA induced signiﬁcant expression of vegf
receptors ﬂt1 (Fig. 5D), kdr (Fig. 5E), and ﬂt4 (Fig. 5F) (P < 0.05 vs.
DU145-xenografted zebraﬁsh).
To examine gene modulation by ZMYND8 in DU145-KOr cells,
qRT-PCR analyses of zebraﬁsh xenografts revealed that ZMYND8
overexpression slightly increased VEGFA expression in cultured
cells (Fig. 5G). However, ZMYND8 overexpression in DU145 cells
did not increase expression of the corresponding zebraﬁsh ortho-
logs (vegfaa and vegfab) in tumour xenografts (Fig. 5H). In sum-
mary, the role of ZMYND8 in tumour angiogenesis of DU145
xenografts depends mainly on the surrounding zebraﬁsh tissues
that regulate vegfa transcription.
4. Discussion
ZMYND8 was initially identiﬁed as a receptor for activated
C-kinase (RACK) protein that binds to activated protein kinase C
beta I (PKCbI) [23]. In cancer research, ZMYND8 has been reported
to be a cutaneous T-cell lymphoma-associated antigen [24].
Recently, a ZMYND8-RELA fusion gene was found to increaseFig. 5. Quantitative RT-PCR analyses of genes involved in the VEGF pathway of ZMYND
modulated, DU145-xenografted zebraﬁsh. Zebraﬁsh zmynd8 modulation altered the exp
(D–F) Expression of zebraﬁsh vegf receptors in zmynd8-modulated, DU145-xenografted z
expression. n = 4, ⁄P < 0.05. (G) Expression of VEGFA mRNA in ZMYND8-modulated,
(HuZMYND8-OE) increased ZMYND8 mRNA expression in DU145-xenografted zebraﬁsh.
the vegf pathway of zebraﬁsh. n = 4, ⁄P < 0.05.leukaemogenically via the NF-jB pathway in acute erythroid leu-
kaemia [25]. ZMYND8 mutation has the highest frequency (19%)
in patients with colorectal cancers [26]. The copy numbers of
ZMYND8 are also increased by 2–3-fold in several cancer cell lines
(Table S4), according to the canSAR database (The Institute of Can-
cer Research, London, UK) and catalogue of somatic mutations in
cancer (COSMIC; Welcome Trust Sanger Institute, Cambridge,
UK). These studies indicate that ZMYND8 is involved in cancer pro-
gression, but the pathophysiological function of ZMYND8 remains
unknown.
In the current study, we discovered that ZMYND8 promotes
tumour angiogenesis and contributes to cancer cell proliferation.
One of the major factors for tumour angiogenesis is hypoxia, and
we found that hypoxia promoted zmynd8 expression in zebraﬁsh
(Fig. S7). An in silico promoter sequence analysis using Pattern
Search for Transcriptional Factor Binding Site (PATCH, public 1.0;
Biobase, Wolfenbuettel, Germany) revealed that human and zebra-
ﬁsh ZMYND8 promoters (3000 bp downstream from the start
codon) have 10 and seven possible HIF1-binding sites, respectively
(Fig. S8), which corresponds to our in vivo results. Based on these
results, zmynd8 would be downstream of HIF-1, which is similar to
another RACK family protein, RACK1 [27]. RACK1 binds to Flt1
(VEGF receptor type 1) directly and regulates the PI3K-Akt-Rac1
pathway in CLL cell migration [27] and hypoxia-induced angiogen-
esis in breast cancer cells [28]. The functional similarity of
ZMYND8 and RACK1 for binding to VEGFRs may exert a hypoxia-
induced angiogenic response. However, ZMYND8 and RACK1
belong to different protein families, and the sequence similarity
of ZMYND8 and RACK1 is quite low (human: 13.2%; zebraﬁsh:
12.9%).
PKC isozymes, in particular PKCb, a binding partner of ZMYND8,
are important mediators of VEGF signalling, and their inhibition
leads to decreased endothelial cell proliferation and a reduction
in neovascularization of malignant tumours [29,30]. Although a8-modulated xenografts in zebraﬁsh. (A–C) Expression of vegf mRNAs in zmynd8-
ression of vegfaa (A) and vegfab (B) mRNAs, but not vegfc mRNA (C). n = 4, ⁄P < 0.05.
ebraﬁsh. Zebraﬁsh zmynd8 modulation increased ﬂt1 (D), kdr (E), and ﬂt4 (F) mRNA
DU145-KOr-xenografted zebraﬁsh. ZMYND8 overexpression in DU145-KOr cells
n = 4, ⁄P < 0.05. (H) HuZMYND8-OE did not alter the expression of genes involved in
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als for several malignancies [31–34], the high degree of sequence
homology and structural similarity of the catalytic regions among
PKC isozymes and other protein kinases suggest that development
of isozyme-selective inhibitors will be extremely challenging [35].
In addition, because multiple PKC isozymes are expressed in all cell
types throughout the body, which perform crucial roles in normal
physiology, systemic inhibition of PKCs may result in undesired
on-target side effects such as delayed wound healing [36]. We also
evaluated PKCb inhibitors Ly317615 and Ly333531 in the xeno-
graft zebraﬁsh model. When these chemicals were exposed to nor-
mal zebraﬁsh at 3–8 dpf, there was a drastic decrease in their
survival rate (Fig. S9). In tumour xenografts, the maximum tolera-
ble concentration of each PKCb inhibitor (Ly317615: 1 lM;
Ly333531: 3 or 10 lM) could not suppress tumour angiogenesis
at 3 dpi (Fig. S10). To overcome these limitations, a new class of
PKC modulator has been developed to inhibit protein–protein
interactions that are crucial for PKC activation, including those
with RACK proteins, because of their high binding speciﬁcity for
PKC isozymes [36]. For example, bIIV5-3, an inhibitor of PKCbII-
RACK1 binding [37], prevents neovascularisation in a xenograft
mouse model of prostate cancer [38]. Based on our results, inhibi-
tion of ZMYND8 (previously known as RACK7) as a co-effector of
PKCbI [23] appears to be a promising approach to modulate PKCbI
activity in the neovascularisation of prostate cancer progression in
the same context. In addition to the direct interaction of ZMYND8
with PKCbI, ZMYND8 binds to formin homology-2-domain con-
taining protein 1 [39] that has several potential PKC phosphoryla-
tion domains [40]. This ﬁnding suggests that ZMYND8 regulates
PKCb phosphorylation and activity as a component of the PKC reg-
ulatory complex. As a PKCbmodulator, ZMYND8 may be a suitable
drug target for inhibition of tumour angiogenesis.
In the current study, zmynd8 regulated vegfa expression during
tumour angiogenesis. Many studies have reported that the PKC
pathway is downstream of VEGF-VEGFR signalling. However, PKC
isozymes are also known to induce VEGFA mRNA expression in
several angiogenic diseases, including cancers, and vice versa [41]
[42]. Considering these observations, ZMYND8 plays a key regula-
tory role in pathological angiogenesis, probably by contributing to
the PKCb-VEGFA axis. In our zebraﬁsh model, ZMYND8 knockdown
could not suppress tumour proliferation (Fig. 2E), despite inhibi-
tion of angiogenesis (Fig. 2D). Drabsch et al. proposed that cancer
xenografts in zebraﬁsh highlight the effects at the early stages of
tumour development [43]. Thus, our results indicate that the early
stage of tumour proliferation was not suppressed by inhibition of
angiogenesis, which is similar to the early stage (2 mm) of human
cancer [44]. In addition, ZMYND8 knockdown in cancer cells could
not suppress tumour angiogenesis (Fig. 4C). However, zmynd8
knockdown in zebraﬁsh suppressed tumour angiogenesis
(Fig. 2D), corresponding to the results showing that human
ZMYND8 knockdown could not reduce VEGFA expression
(Fig. 5G). These results indicate a pathway for tumour angiogenesis
(mainly VEGF signalling), which compensates for human ZMYND8
knockdown in cancer cells but not their surrounding tissues.
ZMYND8 expression was increased in cancer cells and tumour ves-
sels, but the pathological role of these inductions would be
different.
In summary, we show that ZMYND8 is one of the contributing
factors in tumour angiogenesis via VEGFA expression. zmynd8
knockdown zebraﬁsh show no obvious phenotypic changes
(Fig. S4), suggesting that ZMYND8 may be a novel therapeutic tar-
get to inhibit cancer progression without on-target side effects. The
combination of in vivo, in vitro, and in silico data will hopefully
lead to the use of ZMYND8 as a therapeutic target for treatment
of progressive cancers.Financial support
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